GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for INVICTUS

INVICTUS

Official Title

INVestIgation of rheumatiC AF Treatment Using vitamin K antagonists, rivaroxaban or aspirin Studies

Status

Ongoing

Overview

To determine if:

1. In patients with rheumatic valvular heart disease (RVHD) and who are in atrial fibrillation or flutter (AF/flutter) and have other stroke risk factors, rivaroxaban is non-inferior to vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism. 

2. In patients with RVHD, either with AF/flutter but unsuitable for VKA therapy, or with sinus rhythm but with high risk, rivaroxaban is superior to aspirin for prevention of stroke or systemic embolism.

Study Design

One registry and two randomized, parallel group, open-label clinical trials

Primary Endpoint

Stroke and systemic embolism

Number of Patients

17000

Number of Sites

180

Number of Countries

27

Study Period

2016–2020

Principal Investigator

Bongani Mayosi, Stuart J Connolly

Program Manager

Sumathy Rangarajan, Gayle Lewis

Research Coordinator

Amy Krol, Divya Hari

Collaborators

Bayer